Repligen raises 2026 guidance after 13% organic revenue growth in Q2

Repligen Corporation reported second quarter 2026 results on July 28, 2026, for the period ended June 30, 2026. Second quarter revenue reached $204 million, a year-over-year increase of 12% as reported and 13% organic.¹

CEO Olivier Loeillot said the quarter reflected 13% organic growth in the second quarter, reflecting sequential acceleration and continued market outperformance, with order momentum from the first quarter continuing into the second quarter.¹

The company disclosed a definitive agreement to acquire BioLife Solutions. Loeillot said the deal is a key milestone in the company's journey and fast-tracks its cell therapy leadership, in a transaction the company said is accretive to revenue growth, margin, and adjusted EPS.¹ Repligen described the acquisition as adding a differentiated, deeply embedded consumables platform with recurring revenue, commercial-stage exposure, and strong customer workflow integration to its cell therapy position.¹

Separately, the company opened a new Repligen Training & Innovation Center at its OPUS Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands.¹

On guidance, Repligen raised its outlook: total reported revenue guidance moved to $813 million to $835 million, with reported growth of 10% to 13% and organic growth of 10.5% to 13.5%, while diluted adjusted earnings per share guidance moved to $2.03 to $2.09.¹ The company noted its revenue guidance factors in less than half a percentage point of currency benefit alongside roughly a one-point drag tied mainly to the divestiture of Polymem.¹

On cash, Repligen reported cash, cash equivalents and marketable securities of $810 million at June 30, 2026, up from $768 million at December 31, 2025.¹ The guidance figures exclude any potential or pending acquisitions in 2026 and future foreign currency fluctuations, according to the company.¹